Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Hyper-CVAD for Acute Lymphoblastic Leukemia
NCT00671658Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2002
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With a Response up to 210 days. Started Nov 2002; status: completed.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00671658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671658.